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Summary Objective: To assess the usefulness of interleukin-6 (IL-6), tumour necrosis
factor-alpha (TNF-a) and interferon-gamma (IFN-g) in the diagnosis and prediction of
outcome of pleural tuberculosis.
Patients and methods: Pleural fluid from 32 TB and 34 non-TB patients was sent
for assay of IL-6, TNF-a and IFN-g. Clinical parameters at presentation and
residual pleural scarring at completion of treatment were assessed for pleural TB
cases.
Results: The pleural fluid levels of IL-6, TNF-a and IFN-g in TB patients were
significantly higher than those with non-TB effusions (P values of o0.001, 0.018 and
o0.001, respectively by independent t-test). Utility of these cytokines for diagnosis
of pleural TB was evaluated using receiver operating characteristic (ROC) curve
analysis. The cut-off values for IL-6, TNF-a and IFN-g determined in this analysis were
4000, 4 and 60 pg/ml respectively, and their sensitivity and specificity were 90.6% and
76.5%, 90.6% and 79.4%, 100% and 100%, respectively. The pretreatment pleural fluid
IL-6 levels had a positive correlation with the number of febrile days after treatment
(Pearson correlation test: r¼ 0.60, P¼ 0.009). A negative correlation was found
between the percentage reduction in pleural fluid cytokines after 2 weeks treatment
and the extent of residual pleural scarring (IL-6: r¼ –0.62, P¼ 0.041; TNF-a: r¼ –
0.65, P¼ 0.030; IFN-g: r¼ –0.83, P¼ 0.002).
Conclusion: Pleural fluid IL-6, TNF-a and IFN-g assays are useful in the diagnosis of
pleural TB. The initial IL-6 level correlates with the number of febrile days. The
percentage change of cytokines after 2 weeks of treatment also helps to predict
residual pleural scarring.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
Tuberculosis (TB) is still a common and important
infectious disease worldwide.1 Pleural TB is a
common form of extrapulmonary involvement,2
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and TB is a common cause of pleural effusion in
areas with high disease prevalence.3–5
The diagnosis of pleural TB is made from the
characteristic features demonstrated on histologi-
cal examination of pleural tissue, or a positive
culture of Mycobacterium tuberculosis in the
pleural fluid or tissue. However, the sensitivities
of these investigations are limited4,6 and difficulty
in diagnosis of pleural TB is sometimes encoun-
tered.
Pleural TB represents largely an immuno-
logical reaction in which a repertoire of cytokines
is intimately involved in the pathogenesis.
These include especially interleukin-1 (IL-1),7
interleukin-8 (IL-8),8,9 interleukin-6 (IL-6),9–11
tumour necrosis factor (TNF),8,12–15 and interfer-
on-gamma (IFN-g).7,8,12,14,16–21 The measurement
of levels of some of these cytokines has been shown
to be helpful in the diagnosis of pleural
TB.8,13,14,16–19
The present study was undertaken to evaluate
the usefulness of pleural fluid IL-6, TNF-a, IFN-g
in the diagnosis and outcome prediction of pleural
TB.
Materials and methods
Patients
A prospective study was conducted in the Tubercu-
losis and Chest Unit of Grantham Hospital over one
and a half year. Patients who were hospitalized
from January 1999 to June 2000 for management of
pleural effusion were enrolled into the study.
Patients with the diagnosis of TB were regarded
as study subjects. Patients with non-TB effusion
constituted the control group for comparison.
Thoracentesis
All studied patients underwent thoracentesis for
diagnostic purpose. During thoracentesis, pleural
fluid aspirated was sent for biochemical, cytologi-
cal, and microbiological (including mycobacterio-
logical) studies. About 10ml of the pleural fluid was
also saved and stored at 701C for cytokine assay
later. Pleural biopsy was also performed at the
same setting unless the diagnosis was already
known at the time of thoracentesis.
Cytokine assay
The assay of the cytokines in the pleural fluid
samples was carried out in another laboratory of
which the staff was not involved in the clinical
management of the patients. The levels of the
cytokines were measured by the commercially
available enzyme-linked immunosorbant assay (ELI-
SA) kits (Central Laboratory of the Netherlands Red
Cross; Amsterdam, Netherlands) that employed the
quantitative ‘sandwich’ enzyme immunoassay
technique in which a monoclonal antibody against
the specific cytokine was coated onto polystyrene
microtitre wells. A measured volume of the clinical
specimen and eight standard solutions were placed
on the wells, followed by addition of a biotinylated
sheep antibody to the specific cytokine. After
washing off the excess biotinylated antibody,
horseradish peroxidase conjugated streptavidin
was added. After final washing, a substrate was
added. A colour product was then formed in
proportion to the amount of cytokine present in
the sample or the standard. From the measured
colour absorbance, the concentration of the cyto-
kine could be determined by interpolation with the
standard curve.
Diagnosis of Tuberculosis
TB effusion was diagnosed using one of the
following criteria:
1. Pleural biopsy showing granulomatous infla-
mmation together with stainable acid-fast
bacilli.
2. M. tuberculosis isolated from the pleural fluid by
culture.
3. Pleural biopsy showing granulomatous inflamma-
tion, but no stainable acid-fast bacilli, together
with a good radiographic response to anti-
tuberculous treatment.
4. No histological or bacteriological confirmation,
but with other likely alternative diagnoses
excluded, together with a good clinical and
radiographic response to anti-tuberculous treat-
ment.
All patients with pleural TB were given anti-TB
treatment as in-patients for at least 2 weeks
with no adjunctive corticosteroid therapy or
therapeutic drainage. Radiographic resolution of
the pleural effusion at 2 weeks was assessed. A
repeated thoracentesis was performed unless re-
solution of pleural effusion rendered thoracentesis
difficult or the procedure was refused by the
patient.
Chest radiographs of all TB patients were
assessed for residual pleural scarring after comple-
tion of anti-TB treatment.
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Assessment of extent of pleural effusion and
scarring
The amount of pleural effusion at presentation
and after treatment was assessed by measure-
ment of the area of radio-opacity due to pleural
effusion and expressed as a percentage of the
area of the ipsilateral lung field (Fig. 1).
The presence of residual pleural scarring was
defined as presence in any area of thickened
pleural shadow of X10mm on the chest radio-
graph or blunting of the costophrenic angle
to X901. The extent of residual pleural scarring
was assessed by measurement of the area of
radio-opacity from the pleural shadow and
expressed as the percentage of the area of the
ipsilateral lung field. All pleural effusion and
pleural scarring assessments were done by a single
investigator to avoid inter-observer bias in the
assessment.
Statistical Analysis
The statistical analysis of data was done using a
computer software (SPSS Version 8.0). Indepen-
dent t-test was used to compare the cytokine
levels between TB and non-TB patients. Receiver
operating characteristic curve analysis was used
to determine an optimal cut-off value for dia-
gnostic accuracy for each cytokine. Pearson
correlation test was used to study the relation
between cytokine levels and number of febrile
days, and their correlation with the extent
of residual pleural scarring. A P-value of less than
0.05 denotes the presence of statistical signifi-
cance.
Results
Thirty-two cases of pleural TB were enrolled into
the study. They include 23 male and nine female
patients with a mean age of 52.0 years (range: 17–
85 years). All except two cases had diagnosis
confirmed by either pleural biopsy showing granu-
lomatous inflammation or pleural fluid growing
Mycobacterium tuberculosis. Thirty-four cases of
non-TB pleural effusion were recruited as control.
They included 29 cases of malignant effusion (all
due to metastatic carcinoma of lung) and five cases
of transudative effusion (congestive heart fail-
ure¼ 4 and chronic renal failure¼ 1).
The individual values of the three cytokines are
presented in Fig. 2.
Table 1 shows the mean levels of the three
cytokines in the pleural fluid of 32 TB and 34 non-TB
cases. The levels of IL-6, TNF-a and IFN-g in pleural
fluid of the TB patients were significantly higher
than those from non-TB effusions. Diagnostic utility
of these cytokine measurements for TB effusion
was evaluated using ROC curve analysis (Fig. 3).
The cut-off values that give the best diagnostic
accuracy for IL-6, TNF-a and IFN-g determined in
this analysis were 4000, 4 and 60 pg/ml, respec-
tively. Using these cut-off values, the sensitivity,
specificity and the diagnostic accuracy obtained for
each cytokine are shown in Table 2.
Eighteen of the 32 pleural TB cases had fever at
presentation. There was no correlation found
between the presence of fever and any of the
pleural fluid cytokine levels. However, the pleural
fluid IL-6 level was found to have a positive
correlation to the number of febrile days after
the commencement of anti-TB treatment (r¼ 0.60,
P¼ 0.009) (Fig. 4).
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Figure 1 Assessment of extent of pleural effusion.
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Chest radiograph was taken for monitoring of the
amount of effusion for 29 TB patients after 2 weeks
of anti-TB treatment. The amount of pleural
effusion was assessed to be small (less than 15%
of the lung field) in 11 patients, and thus a second
pleural tapping was not attempted. In the remain-
ing 18 cases, 11 agreed to undergo a second
thoracentesis and had fluid sent for cytokine assay.
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Table 1 Values of IL-6, TNF-a and IFN-g in pleural fluid of patients with pleural TB and non-TB effusions
Cytokine TB effusion (n: 32) Non-TB effusion (n: 34) P
Mean (pg/ml) SD Mean (pg/ml) SD
IL-6 76,426 59,229 8,752 20,673 o0.001
TNF-a 27.5 52.2 4.2 9.2 0.018
IFN-g 559.5 718.6 15.6 16.5 o0.001
ROC  Curve  (TNF) ROC Curve (IFN)
0.00 0.20 0.40 0.60 0.80 1.00
1-Specificity
0.00 0.20 0.40 0.60 0.80 1.00
1-Specificity
0.00 0.20 0.40 0.60 0.80 1.00
1-Specificity
IL-6 1-Specificity Sensitivity LR+ LR- 
80000 0.03 0.50 17.00 0.52 
5000 0.24 0.84 3.50 0.21 
4000 0.24 0.91 3.79 0.12 
3500 0.27 0.91 3.37 0.12 
3000 0.29 0.94 3.24 0.08 
2500 0.38 0.97 2.55 0.05 
1000 0.62 1.00 1.62 0.00 
TNF 1-Specificity Sensitivity LR+ LR- 
10   0.44 2.93 0.66 
7 0.72 4.80 0.33 
6 0.81 3.86 0.24 
5 0.88 4.19 0.15 
4 0.91 4.33 0.11
3 0.94 3.48 0.08 
1 1.00 2.27 0.00 
IFN 1-Specificity Sensitivity LR+ LR-
1000 0.00 0.19 0.81
500 0.00 0.25 0.75
100 0.00 0.91 0.09
60 0.00 1.00 0.00
50 0.06 1.00 16.67 0.00
40 0.09 1.00 11.11 0.00
10 0.56 1.00 1.79 0.00
ROC Curve (IL-6)
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Figure 3 Receiver operating characteristic curves for using IL-6, TNF-a and IFN-g for diagnosis of pleural TB (figures in
bold representing the cut-off values for best diagnostic accuracy).
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Figure 2 Individual values of pleural fluid levels of IL-6, TNF-a and IFN-g in pleural TB and non-TB effusion (horizontal
bar representing the means of the values).
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Chest radiographs of 28 patients were evaluated
after completion of TB treatment (one died of
heart disease during treatment, one excluded
because of bacillary multidrug-resistance and two
were lost to follow-up). Eight cases (28.6%) had
residual pleural scarring. There was no correlation
between the pleural fluid cytokine levels and the
presence or the extent of residual pleural scarring.
However, on analysis of the cases in which a second
pleural fluid specimen was taken for cytokine assay,
a statistically significant negative correlation was
found between the percentage reduction of cyto-
kine levels after 2 weeks and the extent of residual
pleural scarring (Fig. 5).
Discussion
TB pleuritis depicts an inflammatory response to
the mycobacteria in the pleural cavity. Mycobac-
terial antigens interact with previously sensitized
T-lymphocytes and cause an immunological or
hypersensitivity reaction.22 Many inflammatory
cells including neutrophils, mononuclear cells,
lymphocytes and mesothelial cells alongside a
complex array of cytokines, are involved in
granuloma formation and alteration of coagulation
locally.23,24 This reaction leads to an increase in
permeability of pleural capillaries and impairment
of clearance of proteins by the lymphatics, result-
ing in the formation of an exudative pleural
effusion.
IL-6, TNF and IFN-g are three important cytokines
putatively involved in the inflammatory process of
the TB effusion. Although they are also found in
other inflammatory or neoplastic conditions of the
pleura, it has been reported in some studies that
these cytokines are markedly elevated in TB as
compared to the other conditions.7–9,11–21 This is
particularly true for IFN-g and the usefulness of this
cytokine in differential diagnosis of pleural TB has
been well reported.14,17–19 However for IL-6, the
diagnostic utility is somewhat conflicting.10,11 For
TNF, Ogawa et al. found elevation of pleural fluid
TNF in both TB and parapneumonic effusion as
compared to malignancy,14 but other reports found
elevation of TNF levels in TB when compared to
other conditions.8,12,13,15
The results of our study showed a significant
difference in the levels of all three cytokines in the
pleural fluid between TB and non-TB patients.
These cytokines, especially IFN-g, can be useful in
enabling the diagnosis of TB pleural effusion. Our
results largely corroborate those of other investi-
gators. However, due to the relatively small sample
size, the cut-off values derived in this study would
preferably be tested on a larger number of patients
with pleural effusion with different etiologies in
the local community to determine whether the
sensitivity and specificity would be acceptable for
the test to be put to clinical use in the diagnosis of
TB effusion.
Pleural fluid IL-6 level was also found to be very
high and correlated with the number of febrile days
after treatment. It might reflect the important role
of this orchestrating cytokine in the induction and
maintenance of inflammatory response25 as well as
its property of an endogenous pyrogen.26,27
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Table 2 Sensitivity, specificity and accuracy in the diagnosis of TB using the best cut-off value for IL-6, TNF-a
and IFN-g in pleural fluid
Cut-off ( pg/ml) Sensitivity (%) Specificity (%) Diagnostic accuracy (%)
IL-6 4,000 90.6 76.5 83.3
TNF-a 4 90.6 79.4 84.8
IFN-g 60 100 100 100
pleural fluid IL-6 level (pg/ml)
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r = 0.60
p < 0.01
Figure 4 Correlation between pretreatment pleural
fluid IL-6 level and the number of febrile days after
treatment in patients with TB effusion (r: Pearson
correlation coefficient).
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There is currently scanty data on the role of
pleural fluid cytokine measurement in the predic-
tion of outcome of pleural TB, in particular the
presence or extent of residual pleural thickening.
De Pablo and colleagues found a higher fluid TNF
level in those patients who developed pleural
thickening than those without pleural thickening.28
A recent study by Kunter and colleagues also
demonstrate a correlation between the develop-
ment and degree of pleural thickening and TNF
level in the pleural fluid.29 In Chinese TB patients,
Hua and colleagues found higher levels of TNF and
IL-1b in the pleural fluid of those with residual
pleural thickening.15 In our study, there was no
correlation between the residual pleural scarring
and the initial fluid levels of any of the three
cytokines. However, a negative correlation was
found between the extent of pleural scarring and
the percentage decrease of the levels of cytokines
in the pleural fluid. This might suggest that the
association between residual pleural scarring and
pleural inflammation rests more on the rate of
resolution of the inflammation rather than its
intensity on presentation. Thus, the proportional
decrease in pleural fluid cytokine levels at 2 weeks
might help in identifying the risk of subsequent
development of pleural scarring. Confirmation of
these findings with a larger sample size would be
useful.
Furthermore, studies on possible therapeutic
interventions in ameliorating this important sequel
appear warranted. At the moment, evidence from
randomized controlled trials regarding hastening of
resorption of pleural effusion by corticosteroids is
equivocal, and does not suggest the value of
corticosteroids in reducing residual pleural thick-
ening.30–33 However, our findings subject to con-
solidation, might enable selection of a more
homogenous patient population for such interven-
tion studies.
Conclusion
Pleural fluid IL-6, TNF-a and IFN-g assays are useful
in the diagnosis of pleural TB. The percentage
change of these cytokines after 2 weeks of
treatment also helps to predict the outcome of
pleural TB.
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